CoChat

PABPN1 gene therapy for oculopharyngeal muscular dystrophy

Malerba, A., Klein, P., Bachtarzi, H., Jarmin, S. A., Cordova, G., Ferry, A., Strings, V., Espinoza, M. Polay, Mamchaoui, K., Blumen, S. C., St Guily, J. Lacau, Mouly, V., Graham, M., Butler-Browne, G., Suhy, D. A., Trollet, C., Dickson, G. · 2017 · Nature Communications
Cited by 89

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Oculopharyngeal muscular dystrophy (OPMD) is an autosomal dominant, late-onset muscle disorder characterized by ptosis, swallowing difficulties, proximal limb weakness and nuclear aggregates in skeletal muscles. OPMD is caused by a trinucleotide repeat expansion in the PABPN1 gene that results in an N-terminal expanded polyalanine tract in polyA-binding protein nuclear 1 (PABPN1). Here we show that the treatment of a mouse model of OPMD with an adeno-associated virus-based gene therapy combining complete knockdown of endogenous PABPN1 and its replacement by a wild-type PABPN1 substantially reduces the amount of insoluble aggregates, decreases muscle fibrosis, reverts muscle strength to the level of healthy muscles and normalizes the muscle transcriptome. The efficacy of the combined treatment is further confirmed in cells derived from OPMD patients. These results pave the way towards a gene replacement approach for OPMD treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/ncomms14848

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 59

  1. Bouchard, J. P., Brais, B., Brunet, D., Gould, P. V. & Rouleau, G. A. Recent studies on oculopharyngeal muscular dystrophy in Quebec. Neuromuscul. Disord. 7, (Suppl 1): S22–S29 (1997). · doi:10.1016/s0960-8966(97)00077-1
  2. Brais, B. et al. Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy. Nat. Genet. 18, 164–167 (1998). · DOI · Paper page
  3. Banerjee, A., Apponi, L. H., Pavlath, G. K. & Corbett, A. H. PABPN1: molecular function and muscle disease. FEBS J. 280, 4230–4250 (2013). · DOI · Paper page
  4. Apponi, L. H. et al. Loss of nuclear poly(A)-binding protein 1 causes defects in myogenesis and mRNA biogenesis. Hum. Mol. Genet. 19, 1058–1065 (2009). · DOI · Paper page
  5. Benoit, B. et al. An essential cytoplasmic function for the nuclear poly(A) binding protein, PABP2, in poly(A) tail length control and early development in Drosophila. Dev. Cell 9, 511–522 (2005). · DOI
  6. de Klerk, E. et al. Poly(A) binding protein nuclear 1 levels affect alternative polyadenylation. Nucleic Acids Res. 40, 9089–9101 (2012). · DOI · Paper page
  7. Jenal, M. et al. The poly(a)-binding protein nuclear 1 suppresses alternative cleavage and polyadenylation sites. Cell 149, 538–553 (2012). · DOI · Paper page
  8. Beaulieu, Y. B., Kleinman, C. L., Landry-Voyer, A. M., Majewski, J. & Bachand, F. Polyadenylation-dependent control of long noncoding RNA expression by the poly(A)-binding protein nuclear 1. PLoS Genet. 8, e1003078 (2012). · DOI · Paper page
  9. Bresson, S. M. & Conrad, N. K. The human nuclear poly(a)-binding protein promotes RNA hyperadenylation and decay. PLoS Genet. 9, e1003893 (2013). · DOI · Paper page
  10. Bergeron, D., Pal, G., Beaulieu, Y. B., Chabot, B. & Bachand, F. Regulated intron retention and nuclear pre-mRNA decay contribute to PABPN1 autoregulation. Mol. Cell Biol. 35, 2503–2517 (2015). · DOI
  11. Muniz, L., Davidson, L. & West, S. Poly(A) polymerase and the nuclear Poly(A) binding protein, PABPN1, coordinate the splicing and degradation of a subset of human pre-mRNAs. Mol. Cell Biol. 35, 2218–2230 (2015). · DOI
  12. Richard, P. et al. PABPN1 (GCN)11 as a dominant allele in oculopharyngeal muscular dystrophy –consequences in clinical diagnosis and genetic counselling. J. Neuromuscul. Dis. 2, 175–180 (2015). · DOI · Paper page
  13. Gidaro, T. et al. Atrophy, fibrosis, and increased PAX7-positive cells in pharyngeal muscles of oculopharyngeal muscular dystrophy patients. J. Neuropathol. Exp. Neurol. 72, 234–243 (2013). · DOI
  14. Tome, F. M. & Fardeau, M. Nuclear inclusions in oculopharyngeal dystrophy. Acta Neuropathol. 49, 85–87 (1980). · DOI
  15. Winklhofer, K. F., Tatzelt, J. & Haass, C. The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. EMBO J. 27, 336–349 (2008). · DOI · Paper page
  16. Conacci-Sorrell, M., Ngouenet, C. & Eisenman, R. N. Myc-nick: a cytoplasmic cleavage product of Myc that promotes alpha-tubulin acetylation and cell differentiation. Cell 142, 480–493 (2010). · DOI · Paper page
  17. Becher, M. W., Kotzuk, J. A., Davis, L. E. & Bear, D. G. Intranuclear inclusions in oculopharyngeal muscular dystrophy contain poly(A) binding protein 2. Ann. Neurol. 48, 812–815 (2000). · doi:10.1002/1531-8249(200011)48:5<812::aid-ana20>3.0.co;2-2
  18. Harish, P., Malerba, A., Dickson, G. & Bachtarzi, H. Progress on gene therapy, cell therapy, and pharmacological strategies toward the treatment of oculopharyngeal muscular dystrophy. Hum. Gene Ther. 26, 286–292 (2015). · DOI
  19. Trollet, C. et al. Molecular and phenotypic characterization of a mouse model of oculopharyngeal muscular dystrophy reveals severe muscular atrophy restricted to fast glycolytic fibres. Hum. Mol. Genet. 19, 2191–2207 (2010). · DOI
  20. Palmer, P. M., Neel, A. T., Sprouls, G. & Morrison, L. Swallow characteristics in patients with oculopharyngeal muscular dystrophy. J. Speech Lang. Hear. Res. 53, 1567–1578 (2010). · doi:10.1044/1092-4388(2010/09-0068
  21. Davies, J. E., Berger, Z. & Rubinsztein, D. C. Oculopharyngeal muscular dystrophy: potential therapies for an aggregate-associated disorder. Int. J. Biochem. Cell Biol. 38, 1457–1462 (2006). · DOI
  22. Davies, J. E. et al. Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice. Nat. Med. 11, 672–677 (2005). · DOI · Paper page
  23. Barbezier, N. et al. Antiprion drugs 6-aminophenanthridine and guanabenz reduce PABPN1 toxicity and aggregation in oculopharyngeal muscular dystrophy. EMBO Mol. Med. 3, 35–49 (2011). · DOI
  24. Davies, J. E., Rose, C., Sarkar, S. & Rubinsztein, D. C. Cystamine suppresses polyalanine toxicity in a mouse model of oculopharyngeal muscular dystrophy. Sci. Transl. Med. 2, 34ra40 (2010). · DOI
  25. Verheesen, P. et al. Prevention of oculopharyngeal muscular dystrophy-associated aggregation of nuclear polyA-binding protein with a single-domain intracellular antibody. Hum. Mol. Genet. 15, 105–111 (2006). · DOI
  26. Perie, S. et al. Autologous myoblast transplantation for oculopharyngeal muscular dystrophy: a Phase I/IIa clinical study. Mol. Ther. 22, 219–225 (2013). · DOI
  27. Chartier, A. et al. Mitochondrial dysfunction reveals the role of mRNA poly(A) tail regulation in oculopharyngeal muscular dystrophy pathogenesis. PLoS Genet. 11, e1005092 (2015). · DOI
  28. Kaeppel, C. et al. A largely random AAV integration profile after LPLD gene therapy. Nat. Med. 19, 889–891 (2013). · DOI · Paper page
  29. Borel, F., Kay, M. A. & Mueller, C. Recombinant AAV as a platform for translating the therapeutic potential of RNA interference. Mol. Ther. 22, 692–701 (2014). · DOI · Paper page
  30. Mendell, J. R. et al. A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. Mol. Ther. 23, 192–201 (2015). · DOI · Paper page
  31. Bisset, D. R. et al. Therapeutic impact of systemic AAV-mediated RNA interference in a mouse model of myotonic dystrophy. Hum. Mol. Genet. 24, 4971–4983 (2015). · DOI
  32. Li, C., Xiao, P., Gray, S. J., Weinberg, M. S. & Samulski, R. J. Combination therapy utilizing shRNA knockdown and an optimized resistant transgene for rescue of diseases caused by misfolded proteins. Proc. Natl Acad. Sci. USA 108, 14258–14263 (2011). · DOI · Paper page
  33. Stanek, L. M. et al. Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease. Hum. Gene Ther. 25, 461–474 (2014). · DOI · Paper page
  34. Wang, Z. et al. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat. Biotechnol. 23, 321–328 (2005). · DOI · Paper page
  35. Kumar, S. R., Markusic, D. M., Biswas, M., High, K. A. & Herzog, R. W. Clinical development of gene therapy: results and lessons from recent successes. Mol. Ther. Methods Clin. Dev. 3, 16034 (2016). · DOI · Paper page
  36. Kharma, N. et al. Automated design of hammerhead ribozymes and validation by targeting the PABPN1 gene transcript. Nucleic Acids Res. 44, e39 (2015). · DOI
  37. O'Reilly, M. et al. RNA interference-mediated suppression and replacement of human rhodopsin in vivo. Am. J. Hum. Genet. 81, 127–135 (2007). · DOI · Paper page
  38. Millington-Ward, S. et al. Suppression and replacement gene therapy for autosomal dominant disease in a murine model of dominant retinitis pigmentosa. Mol. Ther. 19, 642–649 (2011). · DOI · Paper page
  39. Zhang, R. & Lin, Y. DEG 5.0, a database of essential genes in both prokaryotes and eukaryotes. Nucleic Acids Res. 37, D455–D458 (2009). · DOI · Paper page
  40. Apponi, L. H., Corbett, A. H. & Pavlath, G. K. Control of mRNA stability contributes to low levels of nuclear poly(A) binding protein 1 (PABPN1) in skeletal muscle. Skelet. Muscle 3, 23 (2013). · DOI · Paper page
  41. Davies, J. E., Sarkar, S. & Rubinsztein, D. C. Wild-type PABPN1 is anti-apoptotic and reduces toxicity of the oculopharyngeal muscular dystrophy mutation. Hum. Mol. Genet. 17, 1097–1108 (2008). · DOI
  42. Riaz, M. et al. PABPN1-Dependent mRNA Processing Induces Muscle Wasting. PLoS Genet. 12, e1006031 (2016). · DOI
  43. Corbeil-Girard, L. P. et al. PABPN1 overexpression leads to upregulation of genes encoding nuclear proteins that are sequestered in oculopharyngeal muscular dystrophy nuclear inclusions. Neurobiol. Dis. 18, 551–567 (2005). · DOI
  44. Tavanez, J. P., Calado, P., Braga, J., Lafarga, M. & Carmo-Fonseca, M. In vivo aggregation properties of the nuclear poly(A)-binding protein PABPN1. RNA 11, 752–762 (2005). · DOI
  45. Tavanez, J. P. et al. Hsp70 chaperones and type I PRMTs are sequestered at intranuclear inclusions caused by polyalanine expansions in PABPN1. PLoS ONE 4, e6418 (2009). · DOI
  46. Bao, Y. P., Cook, L. J., O'Donovan, D., Uyama, E. & Rubinsztein, D. C. Mammalian, yeast, bacterial, and chemical chaperones reduce aggregate formation and death in a cell model of oculopharyngeal muscular dystrophy. J. Biol. Chem. 277, 12263–12269 (2002). · DOI · Paper page
  47. Fan, X. et al. HnRNP A1 and A/B interaction with PABPN1 in oculopharyngeal muscular dystrophy. Can. J. Neurol. Sci. 30, 244–251 (2003). · DOI
  48. Calado, A. et al. Nuclear inclusions in oculopharyngeal muscular dystrophy consist of poly(A) binding protein 2 aggregates which sequester poly(A) RNA. Hum. Mol. Genet. 9, 2321–2328 (2000). · DOI · Paper page
  49. Bengoechea, R. et al. Nuclear speckles are involved in nuclear aggregation of PABPN1 and in the pathophysiology of oculopharyngeal muscular dystrophy. Neurobiol. Dis. 46, 118–129 (2012). · doi:10.1016/j.nbd.2011.12.052
  50. Klein, P. et al. Nuclear poly(A)-binding protein aggregates misplace a pre-mRNA outside of SC35 speckle causing its abnormal splicing. Nucleic Acids Res. 44, 10929–10945 (2016). · DOI · Paper page
  51. Abu-Baker, A. et al. Involvement of the ubiquitin-proteasome pathway and molecular chaperones in oculopharyngeal muscular dystrophy. Hum. Mol. Genet. 12, 2609–2623 (2003). · DOI
  52. Chartier, A., Benoit, B. & Simonelig, M. A Drosophila model of oculopharyngeal muscular dystrophy reveals intrinsic toxicity of PABPN1. EMBO J. 25, 2253–2262 (2006). · DOI · Paper page
  53. Bigot, A. et al. Large CTG repeats trigger p16-dependent premature senescence in myotonic dystrophy type 1 muscle precursor cells. Am. J. Pathol. 174, 1435–1442 (2009). · DOI
  54. Mamchaoui, K. et al. Immortalized pathological human myoblasts: towards a universal tool for the study of neuromuscular disorders. Skelet. Muscle 1, 34 (2011). · DOI · Paper page
  55. Li, X., Eastman, E. M., Schwartz, R. J. & Draghia-Akli, R. Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences. Nat. Biotechnol. 17, 241–245 (1999). · DOI · Paper page
  56. Vignaud, A. et al. Diabetes provides an unfavorable environment for muscle mass and function after muscle injury in mice. Pathobiology 74, 291–300 (2007). · DOI · Paper page
  57. Carvalho, B. S. & Irizarry, R. A. A framework for oligonucleotide microarray preprocessing. Bioinformatics 26, 2363–2367 (2010). · DOI · Paper page
  58. Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015). · DOI · Paper page
  59. Butler-Browne, G. S., Bugaisky, L. B., Cuenoud, S., Schwartz, K. & Whalen, R. G. Denervation of newborn rat muscle does not block the appearance of adult fast myosin heavy chain. Nature 299, 830–833 (1982). · DOI

Cited by

See all 89

Metadata

Authors
Malerba, A., Klein, P., Bachtarzi, H., Jarmin, S. A., Cordova, G., Ferry, A., Strings, V., Espinoza, M. P., Mamchaoui, K., Blumen, S. C., St Guily, J. L., Mouly, V., Graham, M., Butler-Browne, G., Suhy, D. A., Trollet, C., & Dickson, G.
Venue
Nature Communications
Published
2017-03-31
Volume
8
Issue
1
ISSN
2041-1723
Cited by
89
References
10
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PABPN1 gene therapy for oculopharyngeal muscular dystrophy. https://app.cochat.ai/papers/10.1038/ncomms14848
The paper
Malerba, A., Klein, P., Bachtarzi, H., Jarmin, S. A., Cordova, G., Ferry, A., Strings, V., Espinoza, M. P., Mamchaoui, K., Blumen, S. C., St Guily, J. L., Mouly, V., Graham, M., Butler-Browne, G., Suhy, D. A., Trollet, C., & Dickson, G. (2017). PABPN1 gene therapy for oculopharyngeal muscular dystrophy. Nature Communications. https://doi.org/10.1038/ncomms14848

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.